Healthcare provider profile · identity verified

Jeb Stuart Clark, M.D.

Internal Medicine · TEMPLE, TX · NPI 1609287432

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	368	125
Losartan Potassium	Losartan Potassium	266	89
Levothyroxine Sodium	Levothyroxine Sodium	262	87
Lisinopril	Lisinopril	251	85
Amlodipine Besylate	Amlodipine Besylate	239	86
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	229	28
Gabapentin	Gabapentin	221	79
Simvastatin	Simvastatin	164	61
Hydrochlorothiazide	Hydrochlorothiazide	150	57
Omeprazole	Omeprazole	147	43
Ozempic	Semaglutide	141	26
Tamsulosin Hcl	Tamsulosin Hcl	126	46
Metoprolol Succinate	Metoprolol Succinate	124	37
Metformin Hcl	Metformin Hcl	120	44
Pantoprazole Sodium	Pantoprazole Sodium	103	38
Furosemide	Furosemide	93	35
Trazodone Hcl	Trazodone Hcl	91	38
Carvedilol	Carvedilol	89	29
Fluticasone Propionate	Fluticasone Propionate	86	32
Allopurinol	Allopurinol	85	27
Tramadol Hcl	Tramadol Hcl	79	15
Metoprolol Tartrate	Metoprolol Tartrate	74	25
Celecoxib	Celecoxib	71	26
Metformin Hcl Er	Metformin Hcl	71	30
Duloxetine Hcl	Duloxetine Hcl	68	21
Montelukast Sodium	Montelukast Sodium	65	22
Rosuvastatin Calcium	Rosuvastatin Calcium	63	23
Albuterol Sulfate Hfa	Albuterol Sulfate	58	25
Potassium Chloride	Potassium Chloride	58	20
Fluoxetine Hcl	Fluoxetine Hcl	54	18
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	51	suppressed
Pravastatin Sodium	Pravastatin Sodium	49	18
Jardiance	Empagliflozin	46	17
Glimepiride	Glimepiride	45	14
Eliquis	Apixaban	44	12
Escitalopram Oxalate	Escitalopram Oxalate	43	13
Juluca	Dolutegravir/Rilpivirine	40	suppressed
Mounjaro	Tirzepatide	37	suppressed
Sertraline Hcl	Sertraline Hcl	37	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	36	13
Famotidine	Famotidine	35	14
Finasteride	Finasteride	34	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	34	13
Bupropion Xl	Bupropion Hcl	32	12
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Glipizide	Glipizide	32	11
Azelastine Hcl	Azelastine Hcl	31	12
Methocarbamol	Methocarbamol	30	12
Tivicay	Dolutegravir Sodium	29	suppressed
Propranolol Hcl	Propranolol Hcl	28	suppressed
Baclofen	Baclofen	27	suppressed
Spironolactone	Spironolactone	27	suppressed
Triumeq	Abacavir/Dolutegravir/Lamivudi	27	suppressed
Odefsey	Emtricitab/Rilpiviri/Tenof Ala	26	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	24	suppressed
Cefadroxil	Cefadroxil	23	suppressed
Descovy	Emtricitabine/Tenofov Alafenam	23	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Memantine Hcl	Memantine Hcl	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Ropinirole Hcl	Ropinirole Hcl	22	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	21	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	21	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Clonazepam	Clonazepam	20	suppressed
Dovato	Dolutegravir Sodium/Lamivudine	20	suppressed
Ezetimibe	Ezetimibe	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Diazepam	Diazepam	19	suppressed
Gemfibrozil	Gemfibrozil	19	suppressed
Atenolol	Atenolol	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	18	11
Glipizide Er	Glipizide	18	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Estradiol	Estradiol	17	suppressed
Ondansetron Odt	Ondansetron	17	suppressed
Prezcobix	Darunavir/Cobicistat	17	suppressed
Azithromycin	Azithromycin	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	12	suppressed
Itraconazole	Itraconazole	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Ampicillin Sodium	Ampicillin Sodium	11	suppressed
Flecainide Acetate	Flecainide Acetate	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Vemlidy	Tenofovir Alafenamide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error